An Observational Study of First-Line Maintenance MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: September 11, 2012
Last updated: February 1, 2016
Last verified: February 2016
This prospective observational study will evaluate the safety and efficacy of first-line MabThera/Rituxan (rituximab) maintenance therapy in patients with follicular non-Hodgkin's lymphoma. Patients initiated on MabThera/Rituxan maintenance therapy according to the standard of care and in line with the current summary of product characteristics will be followed for a maximum of two years or until disease progression occurs.

Non-Hodgkin's Lymphoma, Lymphoma, Follicular

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Safety: Incidence of adverse events [ Time Frame: approximately 4 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Response rate [ Time Frame: approximately 4 years ] [ Designated as safety issue: No ]
  • Event free rate [ Time Frame: approximately 4 years ] [ Designated as safety issue: No ]

Enrollment: 22
Study Start Date: October 2012
Estimated Study Completion Date: July 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with follicular non-Hodgkin's lymphoma receiving first-line Rituximab maintenance treatment

Inclusion Criteria:

  • Adult patients (according to local regulation)
  • Patients receiving first-line MabThera/Rituxan maintenance treatment for follicular non-Hodgkin's lymphoma according to the local label and who give consent to take part within 4 weeks after commencing treatment

Exclusion Criteria:

  • Contraindications according to the Summary of Product Characteristics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01684865

Macedonia, The Former Yugoslav Republic of
Skopje, Macedonia, The Former Yugoslav Republic of, 1000
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche Identifier: NCT01684865     History of Changes
Other Study ID Numbers: ML27993 
Study First Received: September 11, 2012
Last Updated: February 1, 2016
Health Authority: Macedonia: Ministry of Health Pharmaceuticals Bureau

Additional relevant MeSH terms:
Lymphoma, Follicular
Lymphoma, Non-Hodgkin
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type processed this record on February 04, 2016